Fig. 2
From: KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
Outcomes with positivity of LB and with KRAS mutations detection. A- OS with positive LB in metastatic disease. B- OS with positive LB in localized disease. C- Hazard ratios (HRs) of OS with mutation detection by LB in metastatic disease. D- HRs of OS with mutation detection in LB in localized disease. E- OS of patients with positive KRAS mutation vs. other mutations in LB for metastatic disease. F- OS of metastatic disease patients with positive KRAS mutation detected by tissue NGS stratified by KRAS mutation detection in LB. G- Frequencies of detected KRAS mutation subtypes. H- OS of patients with KRAS mutation detected in LB by KRAS mutation subtypes